The Cooper Companies, Inc. (NASDAQ:COO) Stock Has Average Price Target of $68.60 According to Brokerages

The Cooper Companies, Inc. (NASDAQ:COO – Get Free Report) has been assigned an average rating of “Hold” from the nineteen ratings firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $68.60.

COO has been the topic of several recent analyst reports. Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a research report on Thursday, September 10th. Weiss Ratings cut Cooper Companies from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 28th. William Blair cut Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday, September 10th. Stifel Nicolaus set a $70.00 price target on Cooper Companies and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Zacks Research lowered Cooper Companies from a “hold” rating to a “strong sell” rating in a report on Friday, September 11th.

Get Our Latest Analysis on Cooper Companies

Cooper Companies Stock Performance

Shares of COO opened at $60.33 on Friday. The company’s 50 day simple moving average is $58.26 and its 200-day simple moving average is $67.75. The firm has a market cap of $11.47 billion, a PE ratio of 20.59, a price-to-earnings-growth ratio of 2.38 and a beta of 0.83. Cooper Companies has a 12-month low of $51.01 and a 12-month high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO – Get Free Report) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts predict that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies announced that its board has approved a share repurchase plan on Wednesday, September 9th that allows the company to repurchase $3 billion in outstanding shares. This repurchase authorization allows the medical device company to buy up to 22.7% of its shares through open market purchases. Share repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Paul A. Keel purchased 4,701 shares of the stock in a transaction dated Friday, September 11th. The shares were acquired at an average cost of $53.18 per share, with a total value of $249,999.18. Following the purchase, the director directly owned 4,701 shares in the company, valued at $249,999.18. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence Kurzius acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were bought at an average cost of $54.93 per share, for a total transaction of $549,300.00. Following the acquisition, the director owned 31,099 shares of the company’s stock, valued at $1,708,268.07. This represents a 47.40% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 34,701 shares of company stock worth $1,880,039. Corporate insiders own 2.08% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Avalon Trust Co purchased a new position in Cooper Companies during the second quarter worth $25,000. Elevation Wealth Partners LLC raised its holdings in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after acquiring an additional 375 shares during the last quarter. Continuum Advisory LLC purchased a new stake in shares of Cooper Companies in the second quarter valued at $30,000. Jacobi Capital Management LLC purchased a new stake in shares of Cooper Companies in the third quarter valued at $25,000. Finally, J.Safra Asset Management Corp purchased a new stake in shares of Cooper Companies in the second quarter valued at $32,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

(Get Free Report)

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.

See Also

Analyst Recommendations for Cooper Companies (NASDAQ:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.